ArticleAME case reports2026
Postmenopausal mixed gestational trophoblastic neoplasia: a case report and review of the literature.
Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mixed gestational trophoblastic neoplasia (GTN) is an exceptionally rare form of GTN, characterized by the coexistence of choriocarcinoma (CC) and/or placental site trophoblastic tumor (PSTT) and/or epithelioid trophoblastic tumor (ETT). GTN rarely presents in women beyond the reproductive age. Case Description: We present a case of a 65-year-old woman diagnosed with mixed GTN (CC + ETT + PSTT). Initially, she was diagnosed with an undefined subtype of GTN, with the possibility of concurrent ovarian and/or endometrial cancer. The patient underwent multi-agent chemotherapy initially and responded well, but she developed severe toxic reaction to the treatment. After symptomatic supportive treatment, she underwent cytoreductive surgery and was given sequential chemotherapy. She responded well but then developed sepsis and other severe side effects. Consequently, the chemotherapy was suspended, and the disease progressed. On the 36th day of the interval, the family decided to discontinue supportive treatment due to financial difficulties, and the patient passed away three days later. We also reviewed 45 cases of mixed GTN from existing literature to deepen clinician understanding of this condition. Conclusions: Mixed GTN is a rare malignant neoplasm of the trophoblastic tissue, particularly in postmenopausal women. The risk of misdiagnosis is high, and definitive treatment protocols remain elusive. Future research must further explore the methods to promote differential diagnosis, chemotherapy and surgery regimens, their timing, and novel therapeutic modalities such as adjuvant immunotherapy, in order to enhance treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.